

RNS Number : 5751R

hVIVO PLC

18 July 2025

hVIVO plc
("hVIVO", the "Company" or the "Group")

Directorate Change

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that the Company has received notice of resignation from Tracey James as Non-Executive Director of the Board with immediate effect. The Company can confirm that Ms James' decision to resign from the Board is unrelated to the Company's financial performance or outlook. The Company's trading update for H1 2025 will be issued on 22 July 2025 as previously announced.

The Nominations Committee has commenced a process to appoint a new independent Non-Executive Director and the Company will announce the results of this process in due course.

Separately, the Nominations Committee is progressing well in its process to appoint a new independent Non-Executive Chair, a further announcement will be made in due course.

For further information please contact:

hVIVO plc Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer	+44 (0)20 7756 1300
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) Geoff Nash, Callum Davidson Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales	+44 (0)20 7220 0500
Peel Hunt LLP (Joint Broker) James Steel, Dr Christopher Golden	+44 (0)20 7418 8900
Davy (Joint Broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings Lianne Applegarth	+44 (0)20 7933 8780 or hvivo@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 804 654 +44 (0)7584 391 303

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.



Notes to Editors

hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the **hLAB** brand.

Through its German subsidiary, **CRS**, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, **Venn Life Sciences** offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via **FluCamp**. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAKZGMNGNDGKZZ